Conference Call with Dr. Lal Pathlabs Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services firm Dr. Lal Pathlabs Announced Q1FY23 Result : Non-Covid revenue up by 25% Covid revenue declined by 91% Normalised EBITDA at Rs 126 Cr with margin at 25% PBT at Rs 81 Cr with margin at 16%, and PAT Rs 58 Cr with margin at 12% Operating Revenue decreased by 17% in Q1 FY23 to Rs. 503 Cr vs Rs 607 Cr in Q1 FY22 Non-Covid Revenue increased by 25% in Q1 FY23 to Rs. 482 Cr vs Rs 386 Cr in Q1 FY22 Covid and Allied contributed 4% to Revenue in Q1 FY23, 36% in Q1 FY22 Normalised EBITDA (after adjustment for stock based compensation, CSR) for Q1 FY21 is at Rs. 126 Cr (margins 25%) Vs Rs 199 Cr in the same quarter last year Normalised PBT at Rs 94 Cr, margins 18.6% vs Rs 179 Cr. in Q1 last year Normalised PAT at Rs 71 Cr, margins 14.0% vs Rs 134 Cr. in Q1 last year Interim Dividend of Rs. 6 per equity share of Rs. 10 each has been approved by the Board Result PDF
Conference Call with Dr. Lal Pathlabs Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.